CAS 1562993-37-6|Ponatinib-d8
Introduction：Basic information about CAS 1562993-37-6|Ponatinib-d8, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Ponatinib-d8 | ||
|---|---|---|---|
| CAS Number | 1562993-37-6 | Molecular Weight | 540.60900 |
| Density | / | Boiling Point | / |
| Molecular Formula | C29H19D8F3N6O | Melting Point | / |
| MSDS | / | Flash Point | / |
Names
| Name | Ponatinib D8 |
|---|---|
| Synonym | More Synonyms |
Ponatinib-d8 BiologicalActivity
| Description | Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. |
|---|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Protein Tyrosine Kinase/RTK >>PDGFRSignaling Pathways >>Protein Tyrosine Kinase/RTK >>SrcSignaling Pathways >>Protein Tyrosine Kinase/RTK >>Bcr-AblSignaling Pathways >>Protein Tyrosine Kinase/RTK >>FGFRSignaling Pathways >>Autophagy >>AutophagySignaling Pathways >>Protein Tyrosine Kinase/RTK >>VEGFR |
| Target | c-Kit:12.5 nM (IC50) VEGFR2:1.5 nM (IC50) FGFR1:2.2 nM (IC50) PDGFRα:1.1 nM (IC50) |
| References | [1]. O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412. |
Chemical & Physical Properties
| Molecular Formula | C29H19D8F3N6O |
|---|---|
| Molecular Weight | 540.60900 |
| Exact Mass | 540.27000 |
| PSA | 65.77000 |
| LogP | 4.40480 |
| InChIKey | PHXJVRSECIGDHY-DHNBGMNGSA-N |
| SMILES | Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12 |
Synonyms
| 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((2,2,3,3,5,5,6,6-octadeutero-4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide |
